NCT06556134View on ClinicalTrials.gov

Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

July 1, 2023

Study Completion Date

January 10, 2024

Conditions
Anemia of Chronic Kidney Disease
Interventions
DRUG

Intravenous Iron Sucrose

Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months

DRUG

Oral Iron

One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid

Trial Locations (1)

30050

Nephrology, Dialysis, and Transplantation, Hassan II University Hospital, Fes

All Listed Sponsors
lead

Centre Hospitalier Hassan II - Fès

OTHER